Merck recently gained approval for a vaccine called Zostavax for preventing herpes zoster reactivation in elderly people. This live virus vaccine is unusual in that it is to prevent reemergence, not to prevent initial infection. Can the same concept be used for recurrent herpes simplex infection which is much more disabling than herpes zoster in younger people?
Dermatologist | Innovator | GenAI Connoisseur | Educator | Software Engineer, coding the future of intelligent medicine! | Consult free if you serve the underprivileged! | Pull requests are always welcome!
Latest posts by Bell Eapen (see all)
- When GenAI Ideas translate to practice with DHTI - March 4, 2026
- How DHTI Makes MCP Practical for Healthcare Through “Docktor” (Part IV) - February 4, 2026
- LLMs, Agentic Patterns, and Practical Healthcare: Why Tools Matter (Part III) - January 28, 2026